Helena Verdaguer

Barcelona, CT, Spain

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 23 publications

A phase III randomized study of first-line NUC-1031/cisplatin vs. gemcitabine/cisplatin in advanced biliary tract cancer.

A phase III randomized study of first-line NUC-1031/cisplatin vs. gemcitabine/cisplatin in advanced biliary tract cancer.

Journal: Journal of hepatology
Published: July 26, 2024

Neoadjuvant sunitinib plus exemestane in post-menopausal women with hormone receptor-positive/HER2-negative early-stage breast cancer (SUT_EXE-08): a phase I/II trial.

Neoadjuvant sunitinib plus exemestane in post-menopausal women with hormone receptor-positive/HER2-negative early-stage breast cancer (SUT_EXE-08): a phase I/II trial.

Journal: Scientific reports
Published: June 15, 2024

The PARP1 selective inhibitor saruparib (AZD5305) elicits potent and durable antitumor activity in patient-derived BRCA1/2-associated cancer models.

The PARP1 selective inhibitor saruparib (AZD5305) elicits potent and durable antitumor activity in patient-derived BRCA1/2-associated cancer models.

Journal: Genome medicine
Published: February 13, 2024

Clinical Outcomes After Progression on First-Line Therapies in IDH1 Mutated Versus Wild-Type Intrahepatic Cholangiocarcinoma Patients.

Clinical Outcomes After Progression on First-Line Therapies in IDH1 Mutated Versus Wild-Type Intrahepatic Cholangiocarcinoma Patients.

Journal: Targeted oncology
Published: November 04, 2022

Human Metastatic Cholangiocarcinoma Patient-Derived Xenografts and Tumoroids for Preclinical Drug Evaluation.

Human Metastatic Cholangiocarcinoma Patient-Derived Xenografts and Tumoroids for Preclinical Drug Evaluation.

Journal: Clinical cancer research : an official journal of the American Association for Cancer Research
Published: August 16, 2022

ACT-Discover: identifying karyotype heterogeneity in pancreatic cancer evolution using ctDNA.

ACT-Discover: identifying karyotype heterogeneity in pancreatic cancer evolution using ctDNA.

Journal: Genome medicine
Published: August 08, 2022

Molecular profile and its clinical impact of IDH1 mutated versus IDH1 wild type intrahepatic cholangiocarcinoma.

Molecular profile and its clinical impact of IDH1 mutated versus IDH1 wild type intrahepatic cholangiocarcinoma.

Journal: Scientific reports
Published: July 18, 2022

Next-generation sequencing analysis of cholangiocarcinoma identifies distinct IDH1-mutated clusters.

Next-generation sequencing analysis of cholangiocarcinoma identifies distinct IDH1-mutated clusters.

Journal: European journal of cancer (Oxford, England : 1990)
Published: June 09, 2022

Phase I, multicenter, open-label study of intravenous VCN-01 oncolytic adenovirus with or without nab-paclitaxel plus gemcitabine in patients with advanced solid tumors.

Phase I, multicenter, open-label study of intravenous VCN-01 oncolytic adenovirus with or without nab-paclitaxel plus gemcitabine in patients with advanced solid tumors.

Journal: Journal for immunotherapy of cancer
Published: March 01, 2022

Advances in the systemic treatment of therapeutic approaches in biliary tract cancer.

Advances in the systemic treatment of therapeutic approaches in biliary tract cancer.

Journal: ESMO open
Published: February 15, 2022

Gene mutational profile of BRCAness and clinical implication in predicting response to platinum-based chemotherapy in patients with intrahepatic cholangiocarcinoma.

Gene mutational profile of BRCAness and clinical implication in predicting response to platinum-based chemotherapy in patients with intrahepatic cholangiocarcinoma.

Journal: European journal of cancer (Oxford, England : 1990)
Published: October 29, 2021

Emerging Treatment Strategies in Pancreatic Cancer.

Emerging Treatment Strategies in Pancreatic Cancer.

Journal: Pancreas
Published: August 16, 2021
Showing 1-12 of 23

Last Updated: 09/26/2026